Screener
OnKure Therapeutics, Inc. OKUR Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by OnKure Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206345
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Other income: | ||
| Interest income | 458 | 1,075 |
| Total other income | 458 | 1,075 |
| Net loss and comprehensive loss | $(15,157) | $(15,925) |
| Net loss per share attributable to common stockholders: | ||
| Basic and diluted | $(1.11) | $(1.19) |
| Weighted average shares outstanding: | ||
| Basic and diluted | 13,674,577 | 13,424,335 |
Item 1. Financial Statements
FAQ
- What is OnKure Therapeutics, Inc.'s net income?
- OnKure Therapeutics, Inc. (OKUR) reported net income of -$15.16M in Q1 2026.
- How has OnKure Therapeutics, Inc.'s net income changed year-over-year?
- OnKure Therapeutics, Inc.'s net income increased by 4.8% year-over-year, from -$15.93M to -$15.16M.
- What is the long-term trend for OnKure Therapeutics, Inc.'s net income?
- Over 3 years (2021 to 2025), OnKure Therapeutics, Inc.'s net income has grown at a 14.4% compound annual growth rate (CAGR), from -$39.77M to -$59.52M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about OnKure Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude